What is Rigel Pharmaceuticals Inc. (New)'s earnings per share (EPS)?

Rigel Pharmaceuticals Inc. (New) (RIGL) reported diluted earnings per share of $19.48 for fiscal year 2025. This represents a 1867.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Rigel Pharmaceuticals Inc. (New) (RIGL) Financials

RIGL

Trailing 12 months to June 30, 2026

Revenue $276.8M +3.3% YoY

Net Income $321.9M +229.1% YoY

EPS (Diluted) $16.88 +211.4% YoY

Operating Cash Flow $79.4M +20.6% YoY

Market Cap $916.8M as of Oct 10, 2026

Price / Sales 3.3x on $276.8M revenue, trailing 12 months to June 30, 2026

Price / Earnings 2.8x on $321.9M net income, trailing 12 months to June 30, 2026

Price / Book 2.2x on $425.4M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 4, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RIGL SEC filings page.

Rigel Pharmaceuticals Inc. (New) (RIGL) reported $276.8M in revenue over the twelve months to Jun 30, 2026, up 3.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RIGL FY2025 2026-10-03

2025 turned Rigel from a loss-making operator into a profitable business, but earnings were amplified by a large tax benefit.

Operating income reached $125M, yet operating cash flow was only $75.7M, so reported operating profit did not convert into equal cash in FY2025. Net income of $367M was lifted far above operating income by a negative tax expense of -$245M, making headline profitability unusually dependent on tax accounting rather than operations.

Revenue climbed from $179M in FY2024 to $294M in FY2025, giving the business more scale to absorb its cost base. Operating margin widened from 13.5% to 42.6%, showing that much of the incremental sales reached operating profit through fixed-cost absorption rather than merely top-line growth.

Equity expanded from $3.3M in FY2024 to $391M in FY2025, materially changing the financing structure. Debt-to-equity fell from 18.2x to 0.1x, while liabilities declined to $122M, so the balance sheet became far less dependent on debt even though cash conversion still lagged operating profit.

Financial Health Signals

Financial Health Score 62/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Rigel Pharmaceuticals Inc. (New)'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Rigel Pharmaceuticals Inc. (New) has an operating margin of 42.6%, meaning the company retains $43 of operating profit per $100 of revenue. This results in a moderate score of 64/100, indicating healthy but not exceptional operating efficiency. This is up from 13.5% the prior year.

Growth

Rigel Pharmaceuticals Inc. (New)'s revenue surged 64.1% year-over-year to $294.3M, reflecting rapid business expansion. This strong growth earns a score of 96/100.

Leverage

Rigel Pharmaceuticals Inc. (New) carries a low D/E ratio of 0.13, meaning only $0.13 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 81/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 2.42, Rigel Pharmaceuticals Inc. (New) holds $2.42 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 69/100.

Cash Flow

Not available for Rigel Pharmaceuticals Inc. (New), and counted as zero in the overall score.

Returns

Rigel Pharmaceuticals Inc. (New)'s ROE of 93.8% shows moderate profitability relative to equity, earning a score of 61/100. This is down from 531.8% the prior year.

Altman Z-Score Safe

3.42

Rigel Pharmaceuticals Inc. (New) scores 3.42, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($916.8M) relative to total liabilities ($122.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

6/9

Rigel Pharmaceuticals Inc. (New) passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.21x

For every $1 of reported earnings, Rigel Pharmaceuticals Inc. (New) generates $0.21 in operating cash flow ($75.7M OCF vs $367.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage Safe

17.14x

Rigel Pharmaceuticals Inc. (New) earns $17.14 in operating income for every $1 of interest expense ($125.5M vs $7.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$78.7M

YoY-22.6%

QoQ+33.8%

5Y CAGR+24.5%

Rigel Pharmaceuticals Inc. (New) generated $78.7M in revenue in Q2 2026. This represents a decrease of 22.6% from the same quarter a year earlier. Against the prior quarter it is up 33.8%.

EBITDA

$24.4M

YoY-60.4%

QoQ+95.7%

Rigel Pharmaceuticals Inc. (New)'s EBITDA was $24.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 60.4% from the same quarter a year earlier. Against the prior quarter it is up 95.7%.

Net Income

$17.3M

YoY-71.0%

QoQ+99.8%

Rigel Pharmaceuticals Inc. (New) reported $17.3M in net income in Q2 2026. This represents a decrease of 71.0% from the same quarter a year earlier. Against the prior quarter it is up 99.8%.

EPS (Diluted)

$0.88

YoY-73.2%

QoQ+100.0%

Rigel Pharmaceuticals Inc. (New) earned $0.88 per diluted share (EPS) in Q2 2026. This represents a decrease of 73.2% from the same quarter a year earlier. Against the prior quarter it is up 100.0%.

Cash & Balance Sheet

Cash & Debt

$60.8M

YoY+13.9%

QoQ+149.1%

5Y CAGR-6.4%

10Y CAGR+9.3%

Rigel Pharmaceuticals Inc. (New) held $60.8M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

19M

YoY+4.1%

QoQ+1.0%

5Y CAGR-35.8%

10Y CAGR-15.0%

Rigel Pharmaceuticals Inc. (New) had 19M shares outstanding in Q2 2026. This represents an increase of 4.1% from the same quarter a year earlier. Against the prior quarter it is up 1.0%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

89.2%

YoY-6.4pp

QoQ-3.0pp

5Y change-10.3pp

Rigel Pharmaceuticals Inc. (New)'s gross margin was 89.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 6.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.0 percentage points.

Operating Margin

29.9%

YoY-30.1pp

QoQ+9.7pp

5Y change+79.6pp

Rigel Pharmaceuticals Inc. (New)'s operating margin was 29.9% in Q2 2026, reflecting core business profitability. This is down 30.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 9.7 percentage points.

Net Margin

22.0%

YoY-36.7pp

QoQ+7.3pp

5Y change+74.6pp

Rigel Pharmaceuticals Inc. (New)'s net profit margin was 22.0% in Q2 2026, showing the share of revenue converted to profit. This is down 36.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.3 percentage points.

Return on Equity

4.1%

YoY-68.7pp

QoQ+1.9pp

Rigel Pharmaceuticals Inc. (New)'s ROE was 4.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 68.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.9 percentage points.

Capital Allocation

R&D Spending

$14.0M

YoY+104.7%

QoQ+19.6%

5Y CAGR-3.6%

Rigel Pharmaceuticals Inc. (New) invested $14.0M in research and development in Q2 2026. This represents an increase of 104.7% from the same quarter a year earlier. Against the prior quarter it is up 19.6%.

Share Buybacks

$511K

QoQ-86.3%

Rigel Pharmaceuticals Inc. (New) spent $511K on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. Against the prior quarter it is down 86.3%.

Capital Expenditures

Not reported for Q2 2026.

RIGL Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RIGL quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$276.8M	$294.3M+64.1%	$179.3M+53.4%	$116.9M-2.8%	$120.2M-19.4%	$149.2M+37.4%	$108.6M+83.2%	$59.3M+33.2%	$44.5M+892.6%	$4.5M-78.0%	$20.4M	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	$23.8M	$19.6M+5.2%	$18.6M+162.3%	$7.1M+306.5%	$1.7M+61.5%	$1.1M+21.0%	$895K-1.2%	$906K+215.7%	$287K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$252.9M	$274.7M+71.0%	$160.6M+46.3%	$109.8M-7.4%	$118.5M-20.0%	$148.2M+37.5%	$107.7M+84.5%	$58.4M+32.0%	$44.2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$43.7M	$33.3M+42.4%	$23.4M-4.7%	$24.5M-59.3%	$60.3M-7.6%	$65.2M+8.5%	$60.1M+13.6%	$52.9M+12.8%	$46.9M+1.4%	$46.3M-27.1%	$63.4M+1.0%	$62.8M-7.2%	$67.7M-10.1%	$75.3M-4.4%	$78.8M+13.6%	$69.3M
SG&A Expenses	$122.2M	$115.9M+2.5%	$113.1M+6.9%	$105.7M-6.0%	$112.5M+22.4%	$91.9M+20.0%	$76.6M+2.7%	$74.6M+6.6%	$70.0M+85.0%	$37.8M+80.9%	$20.9M+17.4%	$17.8M-20.8%	$22.5M+14.7%	$19.6M-14.2%	$22.8M+5.0%	$21.8M
Operating Income	$87.0M	$125.5M+418.6%	$24.2M+218.1%	-$20.5M+63.1%	-$55.5M-344.5%	-$12.5M+56.9%	-$29.0M+58.1%	-$69.1M+4.9%	-$72.7M+8.7%	-$79.6M-14.2%	-$69.7M-34.8%	-$51.7M+43.3%	-$91.2M-2.0%	-$89.5M+10.0%	-$99.4M-15.1%	-$86.4M
EBITDA	N/A	$127.9M+384.0%	$26.4M+237.2%	-$19.3M+64.7%	-$54.6M-381.3%	-$11.3M+59.9%	-$28.3M+58.7%	-$68.4M+5.1%	-$72.1M+8.9%	-$79.2M-15.0%	-$68.8M-36.8%	-$50.3M+43.4%	-$88.9M-2.3%	-$86.9M+10.4%	-$96.9M-14.8%	-$84.4M
Interest Expense	$5.8M	$7.3M-7.6%	$7.9M+15.2%	$6.9M+85.4%	$3.7M-23.7%	$4.9M+259.2%	$1.4M+303.9%	$335K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$25K
Income Tax	-$236.3M	-$245.2M-27931.7%	$881K	$0	N/A	$605K	N/A	N/A	$0	$0	$0	$0	$0	$0	N/A	N/A
Net Income	$321.9M	$367.0M+1999.1%	$17.5M+169.7%	-$25.1M+57.2%	-$58.6M-227.0%	-$17.9M+39.8%	-$29.7M+55.5%	-$66.9M+5.1%	-$70.5M+9.6%	-$78.0M-12.7%	-$69.2M-34.5%	-$51.5M+43.4%	-$90.9M-2.1%	-$89.0M+9.9%	-$98.8M-15.0%	-$86.0M
EPS (Basic)	N/A	$20.40+1960.6%	$0.99+168.7%	-$1.44+58.1%	-$3.44-3027.3%	-$0.11+38.9%	-$0.18+55.0%	-$0.40	N/A	N/A	N/A	N/A	N/A	N/A	-$1.32+2.9%	-$1.36
EPS (Diluted)	$16.88	$19.48+1867.7%	$0.99	-$1.44+58.1%	-$3.44	-$0.11+38.9%	-$0.18+55.0%	-$0.40	N/A	N/A	N/A	N/A	N/A	N/A	-$1.32+2.9%	-$1.36
Diluted Shares (Avg)	N/A	19M+6.5%	18M	17M+2.1%	17M	170M+1.0%	169M+0.8%	167M	N/A	N/A	N/A	N/A	88M+0.4%	87M+16.4%	75M+18.4%	63M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$78.7M-22.6%	$58.8M+10.3%	$69.8M+21.2%	$69.5M+25.6%	$101.7M+176.0%	$53.3M+80.6%	$57.6M+60.9%	$55.3M+96.6%
Cost of Revenue	$8.5M+89.3%	$4.6M+4.5%	$6.0M+2.9%	$4.8M-40.8%	$4.5M+60.5%	$4.4M+117.7%	$5.8M+52.7%	$8.0M+533.0%
Gross Profit	$70.2M-27.8%	$54.2M+10.8%	$63.8M+23.2%	$64.7M+36.9%	$97.2M+185.5%	$48.9M+77.8%	$51.8M+61.9%	$47.3M+76.0%
R&D Expenses	$14.0M+104.7%	$11.7M+38.4%	$10.7M+89.7%	$7.4M+18.9%	$6.8M+23.1%	$8.4M+40.0%	$5.6M+76.8%	$6.2M-4.5%
SG&A Expenses	$32.6M+11.6%	$30.7M+10.6%	$30.0M+1.6%	$28.9M+7.0%	$29.3M+4.3%	$27.7M-2.6%	$29.5M+9.9%	$27.0M+8.8%
Operating Income	$23.6M-61.4%	$11.9M-7.0%	$23.2M+39.1%	$28.4M+102.2%	$61.1M+13569.6%	$12.8M+283.4%	$16.7M+747.2%	$14.1M+414.8%
EBITDA	$24.4M-60.4%	$12.5M-6.7%	$23.8M+37.7%	$29.0M+97.9%	$61.7M+5721.7%	$13.4M+303.7%	$17.3M+664.0%	$14.7M+451.5%
Interest Expense	$800K-57.3%	$1.4M-24.4%	$1.7M-13.1%	$1.9M-8.1%	$1.9M-7.6%	$1.9M-1.1%	$2.0M+2.5%	$2.1M+8.5%
Income Tax	$6.3M+1606.0%	$3.0M+4520.0%	-$245.4M-27949.1%	-$280K	$369K	$65K	$881K	$0
Net Income	$17.3M-71.0%	$8.7M-24.4%	$268.1M+1769.2%	$27.9M+124.6%	$59.6M+5887.7%	$11.4M+238.8%	$14.3M+1845.9%	$12.4M+318.2%
EPS (Basic)	$0.93-72.1%	$0.47-26.6%	$14.88+1737.0%	$1.55+118.3%	$3.33+5650.0%	$0.64+236.2%	$0.81+1520.0%	$0.71+315.2%
EPS (Diluted)	$0.88-73.2%	$0.44-30.2%	$14.10+1640.7%	$1.46+108.6%	$3.28+5566.7%	$0.63	$0.81	$0.70
Diluted Shares (Avg)	20M+7.8%	20M+8.3%	N/A	19M+8.5%	18M+3.5%	18M	N/A	18M

RIGL Balance Sheet

RIGL quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$513.6M+213.2%	$164.0M+39.9%	$117.2M-12.7%	$134.3M-19.8%	$167.3M+51.6%	$110.4M-25.2%	$147.6M+6.1%	$139.1M+16.8%	$119.1M+52.4%	$78.1M-40.7%	$131.7M-14.5%	$154.1M-31.8%	$226.1M-27.1%	$310.0M+20.6%	$257.1M
Current Assets	$240.2M+77.8%	$135.1M+36.1%	$99.3M-14.4%	$115.9M-25.0%	$154.5M+73.6%	$89.0M-25.2%	$119.0M-13.1%	$137.0M+16.7%	$117.4M+54.1%	$76.2M-40.9%	$129.0M-14.3%	$150.5M-31.6%	$220.1M-27.2%	$302.5M+20.9%	$250.2M
Cash & Equivalents	$40.6M-28.5%	$56.7M+73.1%	$32.8M+34.0%	$24.5M+29.5%	$18.9M-37.8%	$30.4M+34.9%	$22.5M-70.5%	$76.3M+99.3%	$38.3M+117.2%	$17.6M-59.4%	$43.5M+185.8%	$15.2M-27.1%	$20.9M-37.7%	$33.5M+79.7%	$18.6M
Short-Term Investments	$114.4M+455.9%	$20.6M-14.8%	$24.1M-28.4%	$33.7M-68.2%	$106.1M+293.5%	$27.0M-64.3%	$75.6M+44.7%	$52.2M-32.6%	$77.5M+35.6%	$57.1M-31.0%	$82.8M-35.3%	$128.0M-33.0%	$191.1M-27.8%	$264.8M+15.6%	$229.0M
Inventory	$11.5M+91.7%	$6.0M+8.7%	$5.5M-39.4%	$9.1M+37.8%	$6.6M+303.9%	$1.6M+21.0%	$1.4M+51.5%	$894K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$51.8M+24.4%	$41.6M+36.2%	$30.6M-24.2%	$40.3M+160.6%	$15.5M-3.1%	$16.0M+58.0%	$10.1M+148.0%	$4.1M	$0	$0-100.0%	$203K-96.5%	$5.8M0.0%	$5.8M	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$122.1M-24.0%	$160.7M+10.2%	$145.9M-1.4%	$147.9M+8.0%	$137.0M+79.4%	$76.4M-18.6%	$93.8M+220.7%	$29.2M+58.3%	$18.5M-20.1%	$23.1M-42.8%	$40.4M+55.9%	$25.9M+45.4%	$17.8M-15.0%	$20.9M0.0%	$21.0M
Current Liabilities	$99.2M+56.8%	$63.3M+18.8%	$53.3M-18.3%	$65.2M+2.6%	$63.6M+55.6%	$40.8M-29.8%	$58.2M+109.9%	$27.7M+51.2%	$18.3M-18.8%	$22.6M-33.2%	$33.8M+141.0%	$14.0M+36.2%	$10.3M-15.7%	$12.2M+5.9%	$11.5M
Non-Current Liabilities	$22.9M-76.5%	$97.4M+5.2%	$92.6M+12.0%	$82.7M+12.6%	$73.4M+106.7%	$35.5M-0.1%	$35.5M+2272.6%	$1.5M+1070.3%	$128K-75.3%	$519K-92.1%	$6.6M-44.6%	$11.9M+57.9%	$7.5M-14.1%	$8.7M-7.3%	$9.4M
Long-Term Debt	$52.5M-12.5%	$60.0M0.0%	$60.0M+50.0%	$40.0M+100.0%	$20.0M0.0%	$20.0M+100.0%	$10.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$391.5M+11806.3%	$3.3M+111.5%	-$28.6M-110.4%	-$13.6M-144.8%	$30.4M-10.7%	$34.0M-36.8%	$53.8M-51.0%	$109.9M+9.2%	$100.6M+82.9%	$55.0M-39.8%	$91.4M-28.7%	$128.2M-38.4%	$208.3M-28.0%	$289.1M+22.4%	$236.1M
Retained Earnings	-$1.0B+26.4%	-$1.4B+1.2%	-$1.4B-1.8%	-$1.4B-4.4%	-$1.3B-1.4%	-$1.3B-2.3%	-$1.3B-5.5%	-$1.2B-6.2%	-$1.1B-7.4%	-$1.1B-7.0%	-$991.6M-5.5%	-$940.2M-10.7%	-$849.3M-11.7%	-$760.2M-14.9%	-$661.4M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$521.1M+152.0%	$504.6M+186.8%	$513.6M+213.2%	$242.5M+74.0%	$206.7M+61.0%	$176.0M+39.1%	$164.0M+39.9%	$139.4M+20.9%
Current Assets	$185.5M+5.8%	$234.0M+59.7%	$240.2M+77.8%	$214.9M+101.9%	$175.4M+85.2%	$146.6M+58.5%	$135.1M+36.1%	$106.5M+12.0%
Cash & Equivalents	$60.8M+13.9%	$24.4M-46.6%	$40.6M-28.5%	$48.5M-6.1%	$53.4M+48.1%	$45.7M+78.8%	$56.7M+73.1%	$51.7M+13.8%
Short-Term Investments	$34.5M-37.2%	$122.3M+289.8%	$114.4M+455.9%	$88.6M+840.4%	$55.0M+321.3%	$31.4M+30.8%	$20.6M-14.8%	$9.4M-44.4%
Inventory	$14.4M+37.8%	$11.7M+150.1%	$11.5M+91.7%	$13.3M+178.1%	$10.4M+29.3%	$4.7M-29.2%	$6.0M+8.7%	$4.8M-21.7%
Accounts Receivable	$56.0M+40.4%	$49.9M+20.2%	$51.8M+24.4%	$45.9M+50.2%	$39.9M+38.1%	$41.5M+51.0%	$41.6M+36.2%	$30.6M+29.9%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$95.6M-23.4%	$104.7M-33.5%	$122.1M-24.0%	$124.9M-18.9%	$124.8M-21.2%	$157.4M-0.5%	$160.7M+10.2%	$154.1M+4.7%
Current Liabilities	$95.6M+10.3%	$89.5M+34.3%	$99.2M+56.8%	$94.4M+73.8%	$86.6M+47.7%	$66.6M-9.0%	$63.3M+18.8%	$54.3M+12.5%
Non-Current Liabilities	$58K-99.8%	$15.2M-83.2%	$22.9M-76.5%	$30.5M-69.4%	$38.2M-61.7%	$90.8M+6.8%	$97.4M+5.2%	$99.7M+0.9%
Long-Term Debt	N/A	$45.0M-25.0%	$52.5M-12.5%	$60.0M0.0%	$60.0M0.0%	$60.0M0.0%	$60.0M0.0%	$60.0M0.0%
Total Equity	$425.4M+419.2%	$399.9M+2053.8%	$391.5M+11806.3%	$117.6M+903.6%	$81.9M+373.9%	$18.6M+158.6%	$3.3M+111.5%	-$14.6M+54.0%
Retained Earnings	-$997.1M+24.4%	-$1.0B+26.4%	-$1.0B+26.4%	-$1.3B+8.1%	-$1.3B+6.9%	-$1.4B+2.6%	-$1.4B+1.2%	-$1.4B+0.3%

Not reported in any period shown, so not listed: Goodwill.

RIGL Cash Flow Statement

RIGL quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$79.4M	$75.7M+140.4%	$31.5M+648.0%	-$5.7M+92.2%	-$73.8M-1354.8%	$5.9M+111.3%	-$52.2M-25.7%	-$41.5M+29.4%	-$58.8M+24.2%	-$77.6M-2.2%	-$75.9M-224.1%	-$23.4M+66.4%	-$69.8M+19.0%	-$86.1M-1.0%	-$85.2M-22.8%	-$69.4M
Depreciation & Amortization	N/A	$2.4M+8.4%	$2.2M+80.0%	$1.2M+24.0%	$998K-14.1%	$1.2M+64.6%	$706K+3.4%	$683K+15.0%	$594K+27.7%	$465K-50.6%	$941K-34.6%	$1.4M-39.0%	$2.4M-9.0%	$2.6M+6.5%	$2.4M+24.5%	$2.0M
Stock-Based Compensation	N/A	$12.7M+2.6%	$12.4M+40.7%	$8.8M-28.9%	$12.4M+30.6%	$9.5M+30.0%	$7.3M-19.9%	$9.1M+18.3%	$7.7M+28.7%	$6.0M-18.4%	$7.3M-0.9%	$7.4M-24.4%	$9.8M+36.6%	$7.2M-43.2%	$12.6M-4.2%	$13.2M
Capital Expenditures	N/A	N/A	N/A	N/A	$450K-28.2%	$627K-50.3%	$1.3M-13.3%	$1.5M+31.6%	$1.1M+574.4%	$164K-79.6%	$804K+47.3%	$546K+32.2%	$413K-66.2%	$1.2M-63.8%	$3.4M+46.6%	$2.3M
Free Cash Flow	N/A	N/A	N/A	N/A	-$74.2M-1513.2%	$5.3M+109.8%	-$53.4M-24.4%	-$43.0M+28.3%	-$59.9M+22.9%	-$77.7M-1.3%	-$76.7M-220.1%	-$24.0M+65.9%	-$70.2M+19.6%	-$87.3M+1.5%	-$88.6M-23.6%	-$71.7M
Investing Cash Flow	-$49.1M	-$92.4M-2336.4%	$4.1M+196.1%	-$4.3M-105.9%	$72.8M+190.9%	-$80.0M-268.6%	$47.5M+300.7%	-$23.7M-194.8%	$25.0M+228.2%	-$19.5M-178.3%	$24.9M-44.2%	$44.6M	N/A	N/A	N/A	N/A
Financing Cash Flow	-$22.9M	$601K+105.2%	-$11.6M-163.4%	$18.4M+180.4%	$6.5M-89.5%	$62.7M+398.6%	$12.6M+10.6%	$11.4M-84.2%	$71.9M-38.9%	$117.7M+367.3%	$25.2M+257.1%	$7.1M	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$30.7M+0.4%	$2.7M+405.2%	$22.0M+51.6%	$24.0M+10.8%	$30.5M+10011.6%	-$893K+82.2%	$14.5M+332.4%	$21.7M+1695.2%
Depreciation & Amortization	$848K+39.7%	$597K-1.2%	$601K-0.5%	$603K-1.3%	$607K-1.0%	$604K+51.0%	$604K+106.1%	$611K+109.2%
Stock-Based Compensation	$6.8M+108.9%	$3.5M+4.0%	N/A	$3.4M+27.2%	$3.3M+29.6%	$3.3M-35.3%	N/A	$2.6M+36.1%
Investing Cash Flow	$17.5M+175.0%	-$8.0M+24.4%	-$25.4M-132.4%	-$33.2M-972.6%	-$23.3M-313.0%	-$10.6M-3471.2%	-$10.9M-58.8%	$3.8M+425.0%
Financing Cash Flow	-$11.7M-2899.3%	-$10.9M-2356.0%	-$4.6M-412.1%	$4.3M+143.4%	$418K+155.6%	$484K+119.3%	$1.5M+201.4%	-$9.8M-1032.6%
Share Buybacks	$511K	$3.7M	N/A	N/A	$0	$0	N/A	N/A

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid.

RIGL Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RIGL quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	93.3%+3.7pp	89.6%-4.3pp	93.9%-4.6pp	98.6%-0.7pp	99.3%+0.1pp	99.2%+0.7pp	98.5%-0.9pp	99.4%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	42.6%+29.1pp	13.5%+31.0pp	-17.5%+28.7pp	-46.2%-37.8pp	-8.4%+18.3pp	-26.7%	-116.5%	-163.3%	-1775.6%	-342.1%	N/A	N/A	N/A	N/A	N/A
Net Margin	124.7%	9.8%+31.2pp	-21.5%+27.2pp	-48.7%-36.7pp	-12.0%+15.4pp	-27.4%	-112.8%	-158.3%	-1739.3%	-339.6%	N/A	N/A	N/A	N/A	N/A
Return on Equity	93.8%-438.0pp	531.8%	N/A	N/A	-59.0%+28.4pp	-87.4%+36.9pp	-124.3%-60.2pp	-64.1%+13.4pp	-77.5%+48.3pp	-125.8%-69.5pp	-56.3%+14.6pp	-70.9%-28.1pp	-42.8%-8.6pp	-34.2%+2.2pp	-36.4%
Return on Assets	71.5%+60.8pp	10.7%+32.1pp	-21.4%+22.2pp	-43.6%-32.9pp	-10.7%+16.2pp	-27.0%+18.4pp	-45.3%+5.3pp	-50.7%+14.8pp	-65.5%+23.1pp	-88.6%-49.5pp	-39.1%+19.9pp	-59.0%-19.6pp	-39.4%-7.5pp	-31.9%+1.6pp	-33.4%
Current Ratio	2.42+0.3x	2.13+0.3x	1.86+0.1x	1.78-0.7x	2.43+0.3x	2.18+0.1x	2.04-2.9x	4.94-1.5x	6.40+3.0x	3.37-0.4x	3.82-6.9x	10.73-10.6x	21.38-3.4x	24.78+3.1x	21.71
Debt-to-Equity	0.13-18.1x	18.25	N/A	N/A	0.66+0.1x	0.59+0.4x	0.19-0.1x	0.27+0.1x	0.18-0.2x	0.420.0x	0.44+0.2x	0.20+0.1x	0.090.0x	0.070.0x	0.09
Asset Turnover	0.57-0.5x	1.09+0.1x	1.00+0.1x	0.900.0x	0.89-0.1x	0.98+0.6x	0.40+0.1x	0.32+0.3x	0.04-0.2x	0.26	N/A	N/A	N/A	N/A	N/A
FCF Margin	N/A	N/A	N/A	-61.7%-65.2pp	3.5%+52.7pp	-49.2%+23.3pp	-72.5%	-134.7%	-1733.3%	-376.3%	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	89.2%-6.4pp	92.2%+0.4pp	91.5%+1.5pp	93.2%+7.7pp	95.6%+3.2pp	91.7%-1.4pp	90.0%+0.5pp	85.5%-10.0pp
Operating Margin	29.9%-30.1pp	20.2%-3.7pp	33.2%+4.3pp	40.9%+15.5pp	60.1%+58.9pp	23.9%+47.5pp	28.9%+23.4pp	25.4%+41.3pp
Net Margin	22.0%-36.7pp	14.7%-6.8pp	384.0%	40.2%+17.7pp	58.6%+61.4pp	21.5%+49.4pp	24.9%+22.8pp	22.5%+42.7pp
Return on Equity	4.1%-68.7pp	2.2%-59.5pp	68.5%-367.7pp	23.7%	72.8%	61.7%	436.2%	N/A
Return on Assets	3.3%-25.5pp	1.7%-4.8pp	52.2%+43.4pp	11.5%+2.6pp	28.8%+29.6pp	6.5%+13.0pp	8.8%+8.1pp	8.9%+13.9pp
Current Ratio	1.94-0.1x	2.62+0.4x	2.42+0.3x	2.28+0.3x	2.02+0.4x	2.20+0.9x	2.13+0.3x	1.960.0x
Debt-to-Equity	0.22-0.5x	0.11-3.1x	0.13-18.1x	0.51	0.73	3.23	18.25	N/A
Asset Turnover	0.15-0.3x	0.12-0.2x	0.14-0.2x	0.29-0.1x	0.49+0.2x	0.30+0.1x	0.350.0x	0.40+0.2x

Not reported in any period shown, so not listed: FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Rigel Pharmaceuticals Inc. (New) RIGL	FY2025	$294.3M	$367.0M	N/A	$916.8M	62/100
Palvella Therapeutics, Inc. PVLA	FY2025	N/A	-$41.7M	N/A	$1.9B	—
Nurix Therapeutics, Inc. NRIX	FY2025	$84.0M	-$264.5M	N/A	$2.3B	54/100
Rezolute, Inc. RZLT	FY2026	N/A	-$77.6M	N/A	$448.8M	—
Terns Pharmaceuticals, Inc. TERN	FY2025	N/A	-$96.2M	N/A	$6.1B	—
AnaptysBio, Inc. ANAB	FY2025	$234.6M	-$13.2M	-5.6%	$1.4B	80/100

Where Rigel Pharmaceuticals Inc. (New) Ranks

Frequently Asked Questions

What is Rigel Pharmaceuticals Inc. (New)'s annual revenue?

Rigel Pharmaceuticals Inc. (New) (RIGL) reported $294.3M in total revenue for fiscal year 2025. This represents a 64.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Rigel Pharmaceuticals Inc. (New)'s revenue growing?

Rigel Pharmaceuticals Inc. (New) (RIGL) revenue grew by 64.1% year-over-year, from $179.3M to $294.3M in fiscal year 2025.

Is Rigel Pharmaceuticals Inc. (New) profitable?

Yes, Rigel Pharmaceuticals Inc. (New) (RIGL) reported a net income of $367.0M in fiscal year 2025.

What is Rigel Pharmaceuticals Inc. (New)'s EBITDA?

Rigel Pharmaceuticals Inc. (New) (RIGL) had EBITDA of $127.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Rigel Pharmaceuticals Inc. (New) have?

As of fiscal year 2025, Rigel Pharmaceuticals Inc. (New) (RIGL) had $40.6M in cash and equivalents against $52.5M in long-term debt.

What is Rigel Pharmaceuticals Inc. (New)'s gross margin?

Rigel Pharmaceuticals Inc. (New) (RIGL) had a gross margin of 93.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Rigel Pharmaceuticals Inc. (New)'s operating margin?

Rigel Pharmaceuticals Inc. (New) (RIGL) had an operating margin of 42.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Rigel Pharmaceuticals Inc. (New)'s return on equity (ROE)?

Rigel Pharmaceuticals Inc. (New) (RIGL) has a return on equity of 93.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Rigel Pharmaceuticals Inc. (New)'s operating cash flow?

Rigel Pharmaceuticals Inc. (New) (RIGL) generated $75.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Rigel Pharmaceuticals Inc. (New)'s total assets?

Rigel Pharmaceuticals Inc. (New) (RIGL) had $513.6M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Rigel Pharmaceuticals Inc. (New) spend on research and development?

Rigel Pharmaceuticals Inc. (New) (RIGL) invested $33.3M in research and development during fiscal year 2025.

How many shares does Rigel Pharmaceuticals Inc. (New) have outstanding?

Rigel Pharmaceuticals Inc. (New) (RIGL) had 18M shares outstanding as of fiscal year 2025.

What is Rigel Pharmaceuticals Inc. (New)'s current ratio?

Rigel Pharmaceuticals Inc. (New) (RIGL) had a current ratio of 2.42 as of fiscal year 2025, which is generally considered healthy.

What is Rigel Pharmaceuticals Inc. (New)'s debt-to-equity ratio?

Rigel Pharmaceuticals Inc. (New) (RIGL) had a debt-to-equity ratio of 0.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Rigel Pharmaceuticals Inc. (New)'s return on assets (ROA)?

Rigel Pharmaceuticals Inc. (New) (RIGL) had a return on assets of 71.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Rigel Pharmaceuticals Inc. (New)'s P/E ratio?

Rigel Pharmaceuticals Inc. (New) (RIGL) trades at 2.8x earnings, its market capitalization divided by net income of $321.9M net income, trailing 12 months to June 30, 2026. The market capitalization is $916.8M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Rigel Pharmaceuticals Inc. (New)'s price-to-sales ratio?

Rigel Pharmaceuticals Inc. (New) (RIGL) trades at 3.3x sales, its market capitalization divided by revenue of $276.8M revenue, trailing 12 months to June 30, 2026. The market capitalization is $916.8M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Rigel Pharmaceuticals Inc. (New)'s Altman Z-Score?

Rigel Pharmaceuticals Inc. (New) (RIGL) has an Altman Z-Score of 3.42, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Rigel Pharmaceuticals Inc. (New)'s Piotroski F-Score?

Rigel Pharmaceuticals Inc. (New) (RIGL) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Rigel Pharmaceuticals Inc. (New)'s earnings high quality?

Rigel Pharmaceuticals Inc. (New) (RIGL) has an earnings quality ratio of 0.21x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Rigel Pharmaceuticals Inc. (New) cover its interest payments?

Rigel Pharmaceuticals Inc. (New) (RIGL) has an interest coverage ratio of 17.14x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Rigel Pharmaceuticals Inc. (New)?

Rigel Pharmaceuticals Inc. (New) (RIGL) scores 62 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.